Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tg Therapeuticscmn (TGTX)

Tg Therapeuticscmn (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,582,413
  • Shares Outstanding, K 154,543
  • Annual Sales, $ 233,660 K
  • Annual Income, $ 12,670 K
  • 60-Month Beta 2.33
  • Price/Sales 11.23
  • Price/Cash Flow 202.46
  • Price/Book 17.08
Trade TGTX with:

Options Overview Details

View History
  • Implied Volatility 51.54% ( +5.81%)
  • Historical Volatility 59.12%
  • IV Percentile 4%
  • IV Rank 23.26%
  • IV High 160.09% on 08/01/23
  • IV Low 18.63% on 05/10/24
  • Put/Call Vol Ratio 0.26
  • Today's Volume 4,779
  • Volume Avg (30-Day) 5,897
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 103,452
  • Open Int (30-Day) 120,242

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.04
  • Number of Estimates 4
  • High Estimate -0.03
  • Low Estimate -0.06
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +88.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.93 +29.23%
on 04/30/24
18.41 -9.23%
on 05/15/24
+2.73 (+19.53%)
since 04/24/24
3-Month
12.93 +29.23%
on 04/30/24
19.02 -12.13%
on 03/07/24
+3.39 (+25.45%)
since 02/23/24
52-Week
6.46 +158.67%
on 10/16/23
29.32 -43.01%
on 06/08/23
-11.26 (-40.26%)
since 05/24/23

Most Recent Stories

More News
Why TG Therapeutics Stock Was Rocketing Higher This Week

The company raised guidance for sales of its drug for relapsing multiple sclerosis.

TGTX : 16.71 (-1.59%)
TG Therapeutics: Q1 Earnings Snapshot

TG Therapeutics: Q1 Earnings Snapshot

TGTX : 16.71 (-1.59%)
TG Therapeutics: Q4 Earnings Snapshot

TG Therapeutics: Q4 Earnings Snapshot

TGTX : 16.71 (-1.59%)
Why TG Therapeutics Stock Is Crushing It Today

The biopharmaceutical company's Q3 update was music to investors' ears.

TGTX : 16.71 (-1.59%)
TG Therapeutics: Q3 Earnings Snapshot

TG Therapeutics: Q3 Earnings Snapshot

TGTX : 16.71 (-1.59%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX). Such...

TGTX : 16.71 (-1.59%)
Why TG Therapeutics Stock Is Crashing Today

The drugmaker delivered a couple of surprises in Q2.

TGTX : 16.71 (-1.59%)
TG Therapeutics: Q2 Earnings Snapshot

TG Therapeutics: Q2 Earnings Snapshot

TGTX : 16.71 (-1.59%)
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today

These three biotech stocks were on the volatile side today.

APLS : 40.61 (+2.34%)
TGTX : 16.71 (-1.59%)
VKTX : 62.75 (+1.92%)
ISEE : 39.95 (+0.38%)
ALPMY : 9.9900 (+1.32%)
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 22.22% and 105.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TGTX : 16.71 (-1.59%)
ICUI : 101.68 (-2.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 17.60
2nd Resistance Point 17.38
1st Resistance Point 17.04
Last Price 16.71
1st Support Level 16.49
2nd Support Level 16.27
3rd Support Level 15.93

See More

52-Week High 29.32
Fibonacci 61.8% 20.59
Fibonacci 50% 17.89
Last Price 16.71
Fibonacci 38.2% 15.19
52-Week Low 6.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar